<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01648478</url>
  </required_header>
  <id_info>
    <org_study_id>2011.705</org_study_id>
    <nct_id>NCT01648478</nct_id>
  </id_info>
  <brief_title>IRAPs (Secreted Insulin Regulated AminoPeptidase): a New Insulin Sensitivity Biomarker</brief_title>
  <acronym>IRAP</acronym>
  <official_title>Evaluation of Plasma IRAP Secreted Protein as a New Insulin Sensitivity Biomarker, Using Hyperinsulinemic Euglycemic Clamp</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cisbio Bioassays</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies have demonstrated defects in the trafficking and translocation of GLUT4
      glucose transporter in skeletal muscle and adipose tissue to be a major cause of insulin
      resistance in humans. IRAP (Secreted Insulin Regulated AminoPeptidase) is a protein which
      collocalizes and is translocated with GLUT4 to the plasma membrane in response to insulin.
      The extracellular domain of IRAP is cleaved and released in the bloodstream.

      Therefore, IRAP plasma concentration could be a good marker of insulin sensitivity.

      In this study the investigators seek to confirm this hypothesis by using the gold standard of
      insulin sensitivity assessment: the hyperinsulinemic-euglycemic clamp.

      It is a multicenter descriptive study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IRAP plasma concentration during the hyperinsulinemic euglycemic clamp</measure>
    <time_frame>30 min before the clamp and during the clamp every 10 min for a duration of 240 min.</time_frame>
    <description>Enzyme-linked Immunosorbsent assay (Sandwich ELISA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose Infusion Rate (GIR)</measure>
    <time_frame>at T90, T100, T110, T120 minutes and T210, T220, T230, T 240 minutes</time_frame>
    <description>It is an average rate of glucose infused at steady state of the first and second level of insulinemia infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxydative stress markers</measure>
    <time_frame>at T0, T120 and T240 min</time_frame>
    <description>TBARS, GSH, GSSG and nitroalbumin assessments</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>It is a hyperinsulinemic-euglycemic clamp.</intervention_name>
    <description>The hyperinsulinemic-euglycemic clamp includes three periods:
A basal period (from T-30 to T0)
The infusion of insulin at a constant rate (first level at 1 mUI.kg-1.min-1 and a second level at 2 mUI.kg-1.min-1) during 4 hours ( to obtain stable hyperinsulinemia)
The infusion of glucose at variable rate (so as to maintain euglycemia)</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women (sex ratio = 1)

          -  Aged from 18 to 35 years

          -  Fasting glycemia &lt; 6mmol/L

          -  Total cholesterol &lt; 7mmol/L

          -  Triglycerides &lt; 1.5 mmol/L

          -  CRPus &lt; 5 mg/L

          -  Creatinine clearance &lt; 80mL/min according to Cockroft formula

          -  Liver enzymes (ALanine AminoTransférase and ASpartate AminoTransférase) &lt; 1.5 times
             normal values

        Exclusion Criteria:

          -  Subject not in compliance with the recommendations of French National Law in force

          -  Medical history of metabolic disease (diabetes, dyslipidemia), endocrine disease,
             renal insufficiency

          -  Drug use that could affect glucose metabolism and the renin angiotensin aldosterone
             system

          -  Blood pressure &gt; 140/90mmHg

          -  Tea and coffee consumption more than 5 cups per day

          -  Subject who smoke more than 5 cigarettes per day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martine LAVILLE, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche en nutrition humaine Rhone-Alpes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de recherche en nutrition humaine Rhone-Alpes</name>
      <address>
        <city>Pierre Bénite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.crnh-rhone-alpes.fr</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2012</study_first_submitted>
  <study_first_submitted_qc>July 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2012</study_first_posted>
  <last_update_submitted>September 10, 2014</last_update_submitted>
  <last_update_submitted_qc>September 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IRAP</keyword>
  <keyword>insulin sensitivity marker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

